Fusen Pharmaceutical Receives Regulatory Approval for "Metformin Empagliflozin Tablets (I)" for Type 2 Diabetes Treatment

Reuters

Sep 15

Fusen Pharmaceutical Receives Regulatory Approval for "Metformin Empagliflozin Tablets (I)" for Type 2 Diabetes Treatment

Fusen Pharmaceutical Company Ltd. has announced that its "Metformin Empagliflozin Tablets (I)" have been approved for marketing by the National Medical Products Administration of China. This compound preparation, consisting of Metformin Hydrochloride and Empagliflozin, is designed to improve blood glucose control in adult patients with type 2 diabetes when used in conjunction with diet control and exercise. The approval marks a significant addition to Fusen Pharmaceutical's product pipeline in diabetes treatment, offering a favorable risk-to-benefit ratio and classified as a Category B medical insurance product. This development is expected to meet the growing demand for diabetes medications due to increasing awareness rates among patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fusen Pharmaceutical Company Ltd. published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2567111623"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567111623\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567111623?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 19:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567111623","market":"us","top_or_hot":-1,"title":"Fusen Pharmaceutical Receives Regulatory Approval for \"Metformin Empagliflozin Tablets (I)\" for Type 2 Diabetes Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fusen Pharmaceutical Receives Regulatory Approval for \"Metformin Empagliflozin Tablets (I)\" for Type 2 Diabetes Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fusen Pharmaceutical Company Ltd. has announced that its \"Metformin Empagliflozin Tablets (I)\" have been approved for marketing by the National Medical Products Administration of China. This compound preparation, consisting of Metformin Hydrochloride and Empagliflozin, is designed to improve blood glucose control in adult patients with type 2 diabetes when used in conjunction with diet control and exercise. The approval marks a significant addition to Fusen Pharmaceutical's product pipeline in diabetes treatment, offering a favorable risk-to-benefit ratio and classified as a Category B medical insurance product. This development is expected to meet the growing demand for diabetes medications due to increasing awareness rates among patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fusen Pharmaceutical Company Ltd. published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fusen Pharmaceutical Receives Regulatory Approval for \"Metformin Empagliflozin Tablets (I)\" for Type 2 Diabetes Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFusen Pharmaceutical Receives Regulatory Approval for \"Metformin Empagliflozin Tablets (I)\" for Type 2 Diabetes Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-15 19:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fusen Pharmaceutical Receives Regulatory Approval for \"Metformin Empagliflozin Tablets (I)\" for Type 2 Diabetes Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fusen Pharmaceutical Company Ltd. has announced that its \"Metformin Empagliflozin Tablets (I)\" have been approved for marketing by the National Medical Products Administration of China. This compound preparation, consisting of Metformin Hydrochloride and Empagliflozin, is designed to improve blood glucose control in adult patients with type 2 diabetes when used in conjunction with diet control and exercise. The approval marks a significant addition to Fusen Pharmaceutical's product pipeline in diabetes treatment, offering a favorable risk-to-benefit ratio and classified as a Category B medical insurance product. This development is expected to meet the growing demand for diabetes medications due to increasing awareness rates among patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fusen Pharmaceutical Company Ltd. published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01652","symbol_name":"福森药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL1RCyjw:1","article_id":"2567111623","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567111623","pubTimestamp":1757936129,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Fusen Pharmaceutical Company Ltd. has announced that its \"Metformin Empagliflozin Tablets \" have been approved for marketing by the National Medical Products Administration of China. This compound preparation, consisting of Metformin Hydrochloride and Empagliflozin, is designed to improve blood glucose control in adult patients with type 2 diabetes when used in conjunction with diet control and exercise. The approval marks a significant addition to Fusen Pharmaceutical's product pipeline in diabetes treatment, offering a favorable risk-to-benefit ratio and classified as a Category B medical insurance product. This development is expected to meet the growing demand for diabetes medications due to increasing awareness rates among patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01652":"福森药业","BK1191":"制药"},"translate_title":"福森药业“二甲双胍恩格列净片（I）”获监管批准用于治疗2型糖尿病","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01652":0.9},"content_text":"Fusen Pharmaceutical Receives Regulatory Approval for \"Metformin Empagliflozin Tablets (I)\" for Type 2 Diabetes Treatment\n    \n\n        Fusen Pharmaceutical Company Ltd. has announced that its \"Metformin Empagliflozin Tablets (I)\" have been approved for marketing by the National Medical Products Administration of China. This compound preparation, consisting of Metformin Hydrochloride and Empagliflozin, is designed to improve blood glucose control in adult patients with type 2 diabetes when used in conjunction with diet control and exercise. The approval marks a significant addition to Fusen Pharmaceutical's product pipeline in diabetes treatment, offering a favorable risk-to-benefit ratio and classified as a Category B medical insurance product. This development is expected to meet the growing demand for diabetes medications due to increasing awareness rates among patients.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fusen Pharmaceutical Company Ltd. published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}